Reporter falls into Shkreli rabbit hole
Martin Shkreli’s rise from a little‑known biotech founder to the “most hated man in America” began long before the infamous Daraprim price hike, and a legal reporter was there to document the early stages of the story.
First contact and the initial report
In January 2015, a legal reporter received a tip that federal authorities were probing Shkreli for fraud. Following journalistic protocol, he reached out for comment. Shkreli called back himself, not a lawyer or public‑relations staff, and told the journalist there was “no story.”
The conversation, captured in the journalist’s notes, showed Shkreli’s irritation and his refusal to reveal who had leaked the information.
Days later, the journalist published the piece.
Related: Adidas roots tied to Nazi-era family feud
Shkreli responded on Twitter, claiming the reporter “confused a situation that was no longer relevant.”
Shkreli’s unexpected visit to prosecutors
Shortly after the story’s publication, Shkreli took an unusual step: he walked into the U.S. Attorney’s Office in Brooklyn, carrying copies of the journalist’s article, and demanded to “get to the bottom of it.”
According to FBI notes, he spent several hours speaking with two assistant U.S. attorneys, two FBI agents, and a paralegal. Shkreli attempted to explain his side of a range of business decisions, including his ouster from Retrophin in 2014, where he blamed a board that “wanted Shkreli to stop tweeting online and he refused.” The agents, however, appeared unconvinced, and Shkreli later told the journalist that the prosecutors seemed to have already formed an opinion.
Despite the media’s portrayal of Shkreli as a villain, the journalist found the personal interactions starkly different from the public image.
Related: What Pharmacies Offer to Help Us: A Comprehensive Overview
From the reporter’s perspective, the experience showed how a single journalist’s coverage can amplify a subject’s notoriety, potentially affecting the subject’s mental state. He admitted feeling uneasy about the role his story might have played in intensifying public scrutiny, a concern that resonates with anyone who has reported on high‑profile figures. While the story brought him professional acclaim, it also highlighted the ethical tension between informing the public and influencing the trajectory of a legal case.
Shkreli’s case continued to evolve. In February 2016, he testified before Congress, invoking the Fifth Amendment and refusing to answer many questions. The hearing turned into a media spectacle, reinforcing the “Pharma Bro” narrative. Yet, the earlier meetings between Shkreli and the journalist painted a more subtle picture: a complicated individual dealing with legal challenges while managing a public persona that many found repellent.
Later reflections by the journalist consider how media coverage shapes public perception of controversial figures.
His notes, the recorded conversations, and the subsequent legal filings together form a fragmented archive that may never fully reconcile the divergent images of Martin Shkreli—both as a corporate provocateur and as a person seeking to control his own story.
